COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Neuropsychiatric Disorders and Epigenetics - 1st Edition - ISBN: 9780128002261, 9780128005279

Neuropsychiatric Disorders and Epigenetics

1st Edition

0.0 star rating Write a review
Editors: Dag Yasui Jacob Peedicayil Dennis Grayson
Hardcover ISBN: 9780128002261
eBook ISBN: 9780128005279
Imprint: Academic Press
Published Date: 29th November 2016
Page Count: 444
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Neuropsychiatric Disorders and Epigenetics is a comprehensive reference for the epigenetic basis of most common neuropsychiatric disorders. The volume is organized into chapters representing individual neuropsychiatric disorders, from addition to obesity contributed by leading experts in their respective fields. The epigenetic aspects of each disorder are discussed, in the context of the full range of epigenetic mechanisms including DNA modification, histone post-translational modification, chromatin organization and non-coding RNA. A particular emphasis is placed on potential epigenetic interventions, when the effects of environmental stimuli on epigenetic states is particularly relevant o disease.

Recent discoveries in epigenetic research enabled by epic advances in genomic technologies have positioned the field for broad translation to therapeutic interventions for previously unmanageable disorders Neuropsychiatric disorders represent a prime target of epigenetic interventions as they are highly debilitating, often chronic diseases with enormous costs to society. Thus, this volume will help define epigenetics as a key player in neuropsychiatric disorders, highlighting the full spectrum of epigenetic mechanisms underlying such disorders and introducing the vast range of epigenetic therapies under development.

Key Features

  • Analyzes the effects of environmental stimuli on epigenetic states that correlate with neuropsychiatric disease induction
  • Reviews the epigenetic basis for common neuropsychiatric disorders, thereby guiding translational therapies for clinicians and mechanistic studies for scientists
  • Extensive use of diagrams, illustrations, tables, and graphical abstracts for each section providing rapid assessment


Graduate level doctoral students, medical students, clinicians, academic scientists, policy makers and applied scientists are the target audience for this volume. The work should appeal to those involved in genetic, biochemical, neuroscience, molecular biologic, pharmaceutical and psychiatric research

Table of Contents

Dag H. Yasui, Jacob Peedicayil and Dennis R. Grayson

Section I. Neuropsychiatric Disorders and Epigenetics: General Aspects
1. Introduction to Neuropsychiatric Disorders and Epigenetics
Dag H. Yasui, Jacob Peedicayil and Dennis R. Grayson

2. Environmental Factors and Epigenetics of Neuropsychiatric Disorders
Anke Hoffmann and Dietmar Spengler

3. Epigenetic Biomarkers in Neuropsychiatric Disorders
Chin-Chuen Lin, Tiao-Lai Huang

Section II: Epigenetics of Neuropsychiatric Disorders
4. Epigenetics and Cognitive Disorders -Translational Aspects
Fabio Coppedè

5. Epigenetics in Pervasive Developmental Disorders - Translational Aspects
Takeo Kubota

6. Epigenetic causes of intellectual disability – the fragile X syndrome paradigm
Elisabetta Tabolacci, Giovanni Neri

7. Epigenetics of Attention-Deficit Hyperactivity Disorder
Nader Perroud, Sébastien Weibel, Jean-Michel Aubry, Alexandre Dayer

8. The epigenetics of brain aging and psychiatric disorders
Huan Gong, Xiangru Xu

9. Epigenetic therapy may alleviate cognitive deficits in Down syndrome by downregulating overexpressed chromosome 21 gene products
Alain D. Dekker, Peter P. De Deyn and Marianne G. Rots

10. Epigenetics and Multiple Sclerosis
Lara Kular, Gonçalo Castelo-Branco and Maja Jagodic

11. Epigenetics and Migraine
Siew Hua Gan and Munvar Miya Shaik

12. The role of epigenetics in the pathophysiology of epilepsy
Sung Min Nam and Kyung-Ok Cho

13. Epigenetic Dysregulation in Brain Tumors and Neurodevelopment
Marco M. Hefti and Nadejda Tsankova

14. Epigenetics and Cerebrovascular Diseases
Carolina Soriano-Tárraga, Jordi Jiménez-Conde and Jaume Roquer

15. Epigenetics and Eating Disorders
Helge Frieling, Vanessa Buchholz

16. Epigenetics in Obesity
Brian M. Shewchuk

17. Epigenetics and Drug Addiction-Translational Aspects
Jian Feng

18. Epigenetics and Alcohol Use Disorders
Sneha Sagarkar and Amul Sakharkar

Section III: Summary and Outlook
19. Summary and Outlook
Dag H. Yasui, Jacob Peedicayil and Dennis R. Grayson


No. of pages:
© Academic Press 2017
29th November 2016
Academic Press
Hardcover ISBN:
eBook ISBN:

About the Editors

Dag Yasui

Dag Yasui is senior project scientist at UC Davis’ Department of Medical Microbiology and Immunology. His current research program is in the field of chromatin and gene expression regulation in autism spectrum disorders.

Affiliations and Expertise

Senior Project Scientist, Department of Medical Microbiology and Immunology, UC Davis, USA

Jacob Peedicayil

Dr. Jacob Peedicayil is a Professor in the Department of Pharmacology and Clinical Pharmacology, at the Christian Medical College in Vellore, India. He has published 46 review papers, 3 book chapters and is engaged in various editorial review boards and journal positions. His interests include theoretical research in psychiatric epigenetics and muscle-based pharmacology.

Affiliations and Expertise

Professor, Department of Pharmacology and Clinical Pharmacology, Christian Medical CollegeProfessor, Department of Pharmacology and Clinical Pharmacology, Christian Medical College

Dennis Grayson

Dr. Grayson has been interested in mechanisms associated with gene expression for over 20 years. He joined the laboratory of Dr. James E. Darnell, Jr. at the Rockefeller University on 1984 to study cell-type specific transcription factors. This led to the identification of HNF3A as a hepatocyte nuclear factor important for activating the expression of multiple genes in hepatocytes. In 1988, Dr. Grayson joined the Fidia-Georgetown Institute for the Neurosciences and with the support of Dr. Erminio Costa, initiated a program in studying gene expression in neurons. From 1994-1998, he moved to the Allegheny University of the Health Sciences in Pittsburgh and developed a program in molecular psychiatry. He continued his interests in psychiatry and joined the Psychiatric Institute in 1998. This represented a unique opportunity to join his long time collaborators, Drs. Costa and Guidotti to pursue molecular underpinnings of schizophrenia. Dr. Grayson has received NRSA post-doctoral support, R01 and K04 funding from the NIH over the years. He has published over 100 papers in peer-reviewed journals and actively reviews NIH grants and post-doctoral fellowships. In addition, Dr. Grayson has been invited to speak at numerous national and international meetings.

Affiliations and Expertise

Professor of Molecular Neuroscience, University of Illinois at Chicago, IL, USA

Ratings and Reviews